On Jul. 29, 2020, Intravacc and Celonic Group, a biopharmaceutical contract development and manufacturing organization (CDMO), announced that they had signed a research agreement to further design, develop and produce a Covid-19 vaccine based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravaccﾒs prorietary Outer Membrane Vesicle (OMV) technology.